tumor-activated
AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development
AbbVie and Xilio Therapeutics Collaborate on $2.1B Deal for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, T-cell engagers, tumor-activated immunotherapies, oncology, collaboration, biobucks deal